Results 11 to 20 of about 8,219 (198)

Upadacitinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science
Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases ...
Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung   +4 more
doaj   +2 more sources

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature [PDF]

Drugs in Context
Upadacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of different rheumatic diseases, including axial spondyloarthritis (axSpA).
Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone   +3 more
doaj   +2 more sources

Treatment of atopic dermatitis with upadacitinib: adcare single center experience [PDF]

Frontiers in Medicine
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina, Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Mar’yana A. Lysenko, Luis Felipe C. Ensina   +15 more
doaj   +2 more sources

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series

Journal of Dermatological Treatment, 2023
Purpose: The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating ...
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi   +6 more
doaj   +2 more sources

Trial of upadacitinib and adalimumab for psoriatic arthritis [PDF]

, 2022
S.1227-1239Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor a inhibitor, in patients who have an inadequate ...
McInnes, I.B., Pangan, A.L., PachecoTena, C., Liu, Y., Jeka, S., Behrens, F., Anderson, J.K., Kishimoto, M., Magrey, M., Merola, J.F., Chen, L., Zueger, P., Wang, X., Liu, J.   +13 more
core   +2 more sources

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program [PDF]

, 2021
Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion of ...
Mysler, E, Cohen, Stanley, Enejosa, JV, Nash, P, Tanaka, Y, Mysler, Eduardo, Da Silva-Tillmann, B, Cohen, S, Shaw, Tim, Da Silva-Tillmann, Barbara, Burmester, G, Tanaka, Yoshiya, Ferguson, Ryan, Nash, Peter, Rigby, W, Liu, J, Rigby, William, Burmester, Gerd, Conaghan, PG, Ferguson, R, Liu, John, Enejosa, Jeffrey V, Conaghan, Philip G, Shaw, T   +23 more
core   +1 more source

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis [PDF]

, 2023
Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)
Mysler, E, Christina Charles-Schoeman, Nasser Khan, Choy, Ernest, Curtis, Jeffrey R., Nash, P, Khan, N, Mysler, Eduardo, Iain B McInnes, Ralph Lippe, Lippe, Ralph, Lippe, R, Eduardo Mysler, Yamaoka, Kunihiro, Choy, E, Jessica Suboticki, Curtis, Jeffrey R, Ernest Choy, Curtis, JR, Shmagel, Anna K., McInnes, Iain B., Suboticki, J, Peter Nash, Shmagel, Anna K, Hannah Palac, Yamaoka, K, Kunihiro Yamaoka, Jeffrey R Curtis, Charles-Schoeman, C, McInnes, IB, Charles-Schoeman, Christina, Nash, Peter, Khan, Nasser, Shmagel, AK, Suboticki, Jessica, McInnes, Iain B, Anna K Shmagel, Palac, Hannah, Palac, H   +38 more
core   +1 more source

Upadacitinib for psoriatic arthritis refractory to biologics : SELECT-PsA 2 [PDF]

, 2020
Background: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying ...
Pangan, Aileen L., Pangan, Aileen L, Papp, Kim, Wang, Xin, Lertratanakul, Apinya, Mease, Philip J., Dokoupilova, Eva, Van den Bosch, Filip, McCaskill, Reva M, Tillett, William, Anderson, Jaclyn K., Zueger, Patrick, Tsuji, Shigeyoshi, Keiserman, Mauro, McCaskill, Reva M., Anderson, Jaclyn K, Zhong, Sheng, Mease, Philip   +17 more
core   +2 more sources

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease [PDF]

, 2023
peer reviewedBACKGROUND: Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under investigation for the treatment of Crohn's disease.
Julian Panés, Boland, Brigid S, Liu, Jianzhong, Panaccione, Remo, Jianzhong Liu, Geert D’Haens, D'Haens, Geert, Mohamed-Eslam F. Mohamed, Reinisch, Walter, Chen, Minhu, Phillips, Charles, Tian Feng, Minhu Chen, Charles Phillips, Walter Reinisch, Dubcenco, Elena, Brigid S. Boland, Mohamed, Mohamed-Eslam F, Edouard Louis, Geng, Ziqian, Jakob Begun, Loftus, Edward V Jr, Jean-Frederic Colombel, Elena Dubcenco, Ana P. Lacerda, Edward V. Loftus, Laurent Peyrin-Biroulet, Remo Panaccione, Ziqian Geng, Louis, Edouard, Hiroshi Nakase, Panés, Julian, Lacerda, Ana P, Feng, Tian, Nakase, Hiroshi, Colombel, Jean-Frederic, Peyrin-Biroulet, Laurent, Begun, Jakob   +37 more
core   +1 more source

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis

, 2021
International audienceObjective: To assess the efficacy and safety of upadacitinib, an oral Janus kinase inhibitor, as monotherapy or in combination with non-biologic DMARDs (nbDMARDs) in patients with PsA.Methods: Pooled data were analysed from patients
Kato, Koji, Ruderman, Eric, M, Ruderman, Eric M, Gossec, Laure, Lesser, Elizabeth, Nash, Peter, Ritchlin, Christopher, Mccaskill, Reva, McDearmon-Blondell, Erin L, Marchesoni, Antonio, Feng, Dai, Anderson, Jaclyn K, Anderson, Jaclyn, K, Richette, Pascal, Mcdearmon-Blondell, Erin, L   +14 more
core   +1 more source